1-2 of 2
Francesco Atzori
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

Free
George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, Javier Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1884–1893.
https://doi.org/10.1158/1078-0432.CCR-12-0652
Published: 02 April 2013
View articletitled, Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Open the PDF for Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Free
Francesco Atzori, Josep Tabernero, Andrés Cervantes, Ludmila Prudkin, Jordi Andreu, Edith Rodríguez-Braun, Amparo Domingo, Jorge Guijarro, Cristina Gamez, Jordi Rodon, Serena Di Cosimo, Holly Brown, Jason Clark, James S. Hardwick, Robert A. Beckman, William D. Hanley, Karl Hsu, Emiliano Calvo, Susana Roselló, Ronald B. Langdon, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6304–6312.
https://doi.org/10.1158/1078-0432.CCR-10-3336
Published: 02 October 2011
View articletitled, A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data